Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133918) titled 'A randomized, open-label, multicenter phase Ib/III clinical trial of trastuzumab regan combined with bevacizumab versus bevacizumab for first-line maintenance treatment of epithelial ovarian cancer' on Oct. 9.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Zhejiang Cancer Hospital
Condition:
Epithelial ovarian cancer without disease progression (PD) after first-line platinum-based dual-drug chemotherapy combined with bevacizumabYNMT
Intervention:
Experimental Group 1:SHR-A1811 (4.0 mg/kg, Q3W) combined with bevacizumab treatment
Experimental Group 2:SHR-A1811 (4.0 mg/kg, Q3W) comb...